Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Nonrandomized, Open-label,Dose Escalation Clinical Trial to Assess the Safety and Efficacy of EXG001 307 After Intravenous Injection in Patients with Spinal Muscular Atrophy Type 1

NCT05614531 is registered in ClinicalTrials.gov with Guangzhou Jiayin Biotech Ltd as lead sponsor.

NCT NCT05614531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Nonrandomized, Open-label,Dose Escalation Clinical Trial to Assess the Safety and Efficacy of EXG001 307 After Intravenous Injection in Patients with Spinal Muscular Atrophy Type 1
Lead sponsor
Guangzhou Jiayin Biotech Ltd
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
February 16, 2023
Completion date
August 31, 2025
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy type i